Skip links

Exclusive Provider of DAXXIFY

Beauty and self-care = confidence

Your skin is your body's largest organ. We feel it's our duty to take care of every square inch. Take a look at our services below.

Exclusive Provider of DAXXIFY

Allure Skin and Laser is excited to introduce DAXXIFY–the only long-lasting, peptide-powered frown line treatment. Allure Skin and Laser is one of the first, exclusive providers to offer this innovative treatment. DAXXIFY is a new, FDA approved neuromodulator, and the only neuromodulator treatment with results that last up to 6-9 months. 

Best used to treat:

  • Frown lines
  • Crow’s feet
  • Forehead wrinkles
  • Can be used decrease sweating in underarms
  • Migraines 

What is DAXXIFY and how is it different?

Neuromodulators (you may be familiar with neuromodulators such as Botox®, Dysport®, and Xeomin®) are used in the treatment of fine lines and wrinkles. Neuromodulators relax muscles by way of a small amount of botulinum toxin. This causes the underlying tissue to relax, creating a smoother appearance of the skin on the area that was treated. Overtime, the effects wear off and the muscle regains full motion, so continued treatment is encouraged to maintain results. 

DAXXIFY is a new, FDA approved neuromodulator to help smooth moderate to severe lines between the brows. It is the only long-lasting frown line treatment powered by a peptide with results that last on average 6 months and up to 9 months for some.*

Conventional injectables last 3 – 4 months and require up to 4 treatments a year to maintain results.

Nearly 90% of patients say they wish results lasted longer. With DAXXIFY you can keep your frown lines smoother for a full year with as few as 2 treatments.*

Before treatment, we encourage you to schedule an in-person consultation to discuss your specific skin care needs and learn which neuromodulator modality is best for you.

Why are peptides important?

All frown line treatments require a special ingredient to stabilize botulinum toxin A, the protein responsible for helping smooth moderate to severe frown lines. For instance, BOTOX® Cosmetic uses human serum albumin (HSA), a blood product, as its stabilizer. Dysport®, another frown line treatment, uses HSA as a stabilizer and cow’s milk protein as a protectant.

DAXXIFY is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts.

Is DAXXIFY well studied?

DAXXIFY was studied in the largest-ever clinical study conducted for a frown line treatment and included more than 2,400 people across different ages and skin types.

  • There were no serious treatment-related side effects in clinical trials for DAXXIFY
  • The active ingredient in DAXXIFY is botulinum toxin type A, an ingredient that has been used in frown line treatments for more than 20 years
  • 96% of people treated with DAXXIFY were satisfied with their results

The US approval of DAXXIFY was based on data from the SAKURA Phase 3 clinical trial program (SAKURA 1,2,3), which included more than 2,700 patients and approximately 4,200 treatments. In the pivotal trials*:

  • 74% of subjects achieved a ≥2-grade improvement in glabellar lines at week 4 per both investigator and patient assessment
  • 88% achieved ≥2-grade improvement at week 4 per investigator assessment
  • 98% of subjects achieved none or mild wrinkle severity at week 4 per investigator assessment
  • 6-month median duration
  • Some patients maintained treatment results at 9 months
  • Results seen as early as 1 day after treatment, typically seen within 2 days

(*Source: Practical Dermatology, Oct 2022)

Is DAXXIFY safe?

No serious reports with DAXXIFY have been made. DAXXIFY is generally safe and well tolerated with no serious treatment-related adverse events reported in the clinical trials and has a safety profile consistent with other currently available neuromodulators in the aesthetics market. The most common treatment-related adverse events with DAXXIFY observed in the pivotal trials were headache (6%) followed by eyelid ptosis (2%) and facial paresis, including facial asymmetry (1%).

For more important safety information about Daxxify, please visit: